Group 1 - The "Innovation Leaders" list for 2025 in Jiangsu has been released, featuring 100 innovators from various industries, including Yin Hongyu, Chairman of Jinghua Pharmaceutical [1][3] - The award aims to discover, cultivate, and promote outstanding technological talents in enterprises, focusing on entrepreneurs, skilled researchers, and craftsmen to enhance innovation vitality in the province [3] - Jinghua Pharmaceutical is committed to innovation, with successful product developments and expansions planned for 2025, achieving significant results [3] Group 2 - Jinghua Pharmaceutical's Wang's Baochi Pill has been successfully registered and listed in Macau, marking it as the first traditional Chinese medicine heritage product to "go global" [3] - The company has made advancements in product research, with the Jide Sheng Snake Medicine Tablet showing significant efficacy for shingles symptoms and being included in expert consensus guidelines [3] - The company has integrated ESG principles into its strategic operations, achieving high standards in compliance and receiving the "2025 Annual ESG Value Transmission Award" for its contributions to sustainable development [4] Group 3 - Looking ahead to the 14th Five-Year Plan, Jinghua Pharmaceutical aims to strengthen its dual focus on traditional Chinese medicine and raw materials while entering the health industry, creating a new development model with collaborative efforts [4]

Core Insights - The event showcased over 1,000 smart health and rehabilitation devices, indicating a shift towards practical applications of smart elderly care technology [1][2] - The theme of the event emphasized the integration of digital technology with elderly health services, highlighting strategic partnerships and the signing of multiple biopharmaceutical projects [1] - The introduction of a "1+3+N" smart elderly care solution demonstrates the use of big data to enhance the elderly care service system, creating a comprehensive safety net for seniors [1] Industry Developments - The event featured innovative technologies and products in the rehabilitation sector, establishing a seamless service system connecting hospitals, communities, and homes to meet diverse rehabilitation needs of the elderly [2] - Nantong, recognized as a "Longevity Town," is actively implementing health initiatives and addressing population aging, aiming to create a high-quality population service system across all life stages [2] - Nantong has been awarded as a national model city for health city construction for three consecutive years and has established a long-term care insurance system, showcasing its commitment to elderly care [2]

Core Viewpoint - The company Jinghua Pharmaceutical (002349.SZ) does not currently produce any drugs specifically for the treatment of respiratory syncytial virus (RSV) [1] Product Overview - The company's product Qingzhai Hu Yin Granules is used for symptoms such as fever, chills, headache, nasal congestion, sneezing, throat itching, cough, and limb soreness, suitable for initial stages of influenza and mild upper respiratory infections [1] - The product Wang's Baochi Pill is effective for pediatric conditions like milk stagnation, phlegm-induced seizures, cough with phlegm, reduced milk intake, diarrhea with fever, seasonal colds, as well as for adults with gastrointestinal issues [1] - The product Jin Qiao Mai Pian has functions of clearing heat and detoxifying, promoting pus discharge, and relieving cough and asthma, mainly used for acute lung abscess, acute and chronic bronchitis, asthma, and bacterial dysentery [1] - The product Ji Desheng Snake Medicine Tablets has effects of clearing heat and detoxifying, reducing swelling and relieving pain, treating snake and insect bites, and has unique efficacy against viral infections, bacterial infections, and immune deficiencies [1]

Core Viewpoint - The company demonstrates resilience and growth potential in a complex industry environment, with steady revenue growth, significant cash flow improvement, and enhanced competitiveness of core products, alongside advancing internationalization and R&D innovation [1]. Financial Performance - For the first half of 2025, the company achieved revenue of 731 million yuan, a year-on-year increase of 1.54%; net profit attributable to shareholders was 131 million yuan, with a net profit of 127 million yuan after excluding non-recurring gains and losses, indicating solid profitability in core operations [2]. - The net cash flow from operating activities surged by 31.87% to 128 million yuan, reflecting improved operational quality and enhanced capital management efficiency [2]. Core Product Strength - Sales revenue from traditional Chinese medicine preparations grew by 12.45% year-on-year to 287 million yuan, serving as a key support for performance [3]. - Key products such as "Wang's Baochi Pill," "Jide Sheng Snake Medicine Tablets," and "Zheng Chai Hu Drink Granules" continue to gain clinical and market recognition due to their unique efficacy and strong brand heritage [3]. - "Wang's Baochi Pill" was included in the "International Clinical Practice Guidelines for Functional Dyspepsia in Traditional Chinese Medicine (2025 Edition)," enhancing its international influence [3]. International Expansion - The company actively expanded its overseas market, achieving self-operated export sales of 11.3 million USD, a year-on-year increase of 16% [4]. - Several raw material drug varieties have received FDA and CEP certifications, gaining international quality recognition [4]. R&D and Capacity Development - The company places high importance on R&D investment, collaborating with universities on various pharmacological and clinical research projects [5]. - The approval of new indications for "Diphenhydramine Hydrochloride Tablets" by the National Medical Products Administration further enriches the product line [5]. - Projects for traditional Chinese medicine preparation production bases, GMP certification upgrades, and energy-saving renovations are progressing steadily, laying the foundation for future capacity release and quality upgrades [5]. Cost Reduction and Efficiency Improvement - Through process optimization, intelligent equipment upgrades, and procurement cost control, the company achieved cost reductions exceeding 5 million yuan in the first half of the year [6]. - A successful stock incentive plan was implemented in May, granting 15.494 million restricted shares to 105 core employees, effectively motivating the team for long-term development [6]. Social Responsibility - The company continues to promote the construction of GAP bases for Chinese medicinal materials in Gansu Longxi, adopting a "leading enterprise + base + cooperative" model to boost local farmers' income [7]. - During the reporting period, the company procured local medicinal materials worth 30.946 million yuan, creating over 70 jobs, showcasing the responsibility and commitment of state-owned enterprises [7].